CNS Pharmaceuticals Appoints Rami Levin as President and CEO to Advance Brain Cancer Pipeline

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company developing treatments for primary and metastatic cancers of the brain and central nervous system, has announced a leadership transition with Rami Levin, MBA, appointed as president and chief executive officer effective January 1, 2026. This appointment follows John Climaco stepping down as CEO, marking a strategic shift for the company as it prepares to advance its clinical pipeline. Levin brings nearly three decades of global leadership experience across oncology, neurology and rare diseases, with a demonstrated track record of advancing late-stage clinical programs, scaling organizations and leading strategic turnarounds.

The leadership change positions CNS Pharmaceuticals to accelerate development of its promising drug candidates, particularly TPI 287, an abeotaxane that stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. Initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat central nervous system tumors, representing a significant advancement in treating these difficult-to-access cancers. TPI 287 has been tested in over 350 patients across multiple clinical trials as both monotherapy and in combination with bevacizumab for various conditions including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain.

To date, TPI 287 appears to have both an excellent safety profile and high tolerability among patients, making it a promising candidate in the challenging field of brain cancer therapeutics. The drug's ability to potentially cross the blood-brain barrier addresses a critical limitation in current brain cancer treatments, where many therapeutic agents cannot effectively reach tumor sites within the central nervous system. This appointment comes at a crucial time for CNS Pharmaceuticals as the company prepares for the next phase of clinical development and potential regulatory milestones.

The company's focus on developing treatments for primary and metastatic brain cancers addresses a significant unmet medical need, as these cancers remain among the most difficult to treat with current therapeutic options. Levin's extensive experience in oncology and neurology, combined with his background in scaling organizations and advancing late-stage clinical programs, provides CNS Pharmaceuticals with leadership well-suited to navigate the complex regulatory and development landscape of central nervous system cancer therapeutics. The latest news and updates relating to CNSP are available in the company's newsroom at https://ibn.fm/CNSP. This leadership transition represents a strategic move to strengthen the company's position in developing innovative treatments for some of the most challenging cancers affecting patients worldwide.